The remote control doesn’t trigger the self-destruction of the CAR T cells, but simply prompts them to disengage from their cancerous targets.
Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date - Dose-dependent anti-tumo ...
A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results